Caitlynn Mirabelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caitlynn Mirabelli has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
27 shared publications - John Heath
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
27 shared publications - Josie Ursini-Siegel
Division of Experimental Medicine, McGill University, Montreal, Canada
27 shared publications - Peter M. Siegel
Goodman Cancer Institute, McGill University, Montreal, Canada
27 shared publications - Valerie Sabourin
Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada
27 shared publications - Alexandre Orthwein
Emory University School of Medicine
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 6 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 6 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 7 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 7 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 5 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 5 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 3 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 3 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 4 with Legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 4 with Legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 2 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 2 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Tables S1 and S2 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplementary Table 1: Oligonucleotides employed in this study. Supplementary Table 2: Antibodies used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTables S1 and S2 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplementary Table 1: Oligonucleotides employed in this study. Supplementary Table 2: Antibodies used in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 1 with legend
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
Supplemental Figure 1 with legend
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
The pogo transposable element–derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple-negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Although POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade.Significance:The POGZ neurodevelopmental protein plays dual functions in triple-negative breast cancers as a tumor promoter and metastasis suppressor, inhibiting TGFβ-regulated EMT to limit breast cancer metastatic progression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling
The pogo transposable element–derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple-negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Although POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade.Significance:The POGZ neurodevelopmental protein plays dual functions in triple-negative breast cancers as a tumor promoter and metastasis suppressor, inhibiting TGFβ-regulated EMT to limit breast cancer metastatic progression.
- Open Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadu5915
Open AccessComplex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils
Although effective for immunologically hot tumors, immune checkpoint inhibitors minimally affect tumors that are not T cell inflamed, including breast cancer. An alternate strategy to combat immune cold breast tumors may be to reeducate innate immunity. This study identifies strategies to skew neutrophils to acquire tumoricidal properties. Systemic Toll-like receptor (TLR)–induced inflammation, concomitant with mitochondrial complex I inhibition in breast tumors, increases neutrophil cytotoxicity against breast cancer cells and independently of CD8+ T cell immunity. These therapy-entrained neutrophils enhance secretory granule production, increasing expression of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase machinery and inducing a respiratory burst. Moreover, systemic administration of TLR agonists elevates nuclear factor κB signaling in neutrophils to increase production of secretory granule and NADPH oxidase machinery components, whereas complex I inhibitors are required to potentiate oxidative damage. In summary, we describe a class of neutrophils, educated by the combined action of inflammatory mediators and metabolic inhibitors, having tumoricidal functions.